*By Carlo Versano* At the end of a week that saw the nascent cannabis sector soar to record valuations (with enough [volatility](https://cheddar.com/videos/making-sense-of-tilrays-stock-chart) to make your head spin), at least one exec isn't getting high off his own supply. Bruce Linton, CEO of Canopy Growth ($CGC), told Cheddar Friday that he is focused on using a recent $4 billion cash injection from Constellation Brands to accelerate his business operations as new markets open up for legal marijuana use. The market for legal pot went from a handful of countries like Canada, where Canopy is based, to now over 30 globally, Linton said in an interview, and Constellation's stake "is the kind of rocket fuel we need." As speculators send the stocks higher ー Canopy is up 100 percent since the August deal, while Tilray ($TLRY) is up 1,000 percent since its July IPO ー Linton is keeping his nose to the grindstone developing new uses for cannabis, illustrated by the 39 patents Canopy filed in the last year just for sleep-related cannabinoid products. He sees other uses as well, from anxiety to sports recovery, which begs the question: is Canopy a pharma company? "We're going to have enough intellectual property and activity that it would be difficult for pharma companies...not to need to play with us," Linton said. "We're going to disrupt the heck out of them." Speaking of disruption, Linton said he wasn't bothered by parallels with the dot-com bubble of the early 2000s. He said Canopy had more in common with a Google or Amazon ー established businesses with strong fundamentals ー than any of the internet stocks that were relegated to the tech boneyard after the bubble popped. But for an industry like cannabis that is entirely dependent on regulation, there will always be a risk, Linton noted. For every country like Canada, which legalized medical marijuana in 2001 and will allow recreational use starting October 17, there's an Italy ー where medical marijuana is legal but heavily restricted ー or a Japan ー where it is strictly outlawed. Put another way, Canopy may have the best legal pot cultivation and distribution in the world, but its long-term success on a global scale may be capped by shifting regulatory and political climates. Still, Linton sees the writing on the wall in places like South America, Australia, and the EU. As regulatory barriers come down, he said Canopy's strong production operations will lead the market. "People can fight for who's going to be the second best," Linton said. "We're going to be the best and the largest and the most dominant on the planet over the next decade." For full interview [click here](https://cheddar.com/videos/canopy-growth-blazing-a-trail).

Share:
More In Business
Stocks Close Lower As Investors Eye Fed Announcement, GDP, Earnings, & More
Stocks closed lower Thursday amid continued volatility. The S&P 500 was down 10% from its record high, the Dow was down 7%, and the Nasdaq was 4% away from bear market territory as it closed 16% below its record high. Investors are still processing this week's Federal Reserve announcement about a potential first rate hike in March. Chris Gaffney, President of World Markets at TIAA Bank, joins Cheddar News' Closing Bell to discuss today's close, the Fed's announcement, predictions about interest rate hikes, and more.
Crowdbotics Raises $22M Series A to Enable Anyone to Turn Ideas Into Apps
Low-code app development platform Crowdbotics raised $22 million in a Series A funding round led by Jackson Square Ventures. Crowdbotics has helped more than 14,000 customers launch apps without having to learn how to code. The company can offer a team of expert developers to help companies launch custom apps, or provide the means for companies to develop apps themselves. Crowdbotics CEO Anand Kulkarni joined Cheddar News' Closing Bell to discuss.
McDonald's Posts Q4 Earnings Miss; McPlant Burger Takes Off
McDonald's missed on both the top and bottom lines in its Q4 earnings, marking the fourth loss for the fast-food giant in the past eight quarters. It comes as higher costs from food to wages ate into the blue-chip company's profits. George Seay, CEO of investment advisor Annandale Capital, joined Wake Up with Cheddar to discuss the recent numbers and the better-than-expected success of the McPlant burger made with plant-based Beyond Meat. "They're changing with the times, and they have to," Seay noted. "You can just sell a Big Mac to everybody. There's a lot of people who don't want to eat a Big Mac anymore."
Moderna's Chief Medical Officer on Omicron Booster Trial, Annual Shots
Moderna launched a clinical trial of a COVID-19 booster shot specifically targeting the omicron variant. The first participant has already received a dose, and Moderna expects to enroll about 600 adults total, split between two groups. In the first group, participants will have previously received two doses of the Moderna vaccine, and in the second, participants will have received its booster. Dr. Paul Burton, chief medical officer at Moderna, joined Cheddar’s Opening Bell to discuss the trial, yearly boosters, and what lies ahead for the company.
Load More